Abstract:Coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to most of countries in the world, threatening the health and lives of many people. Unfortunately, information regarding the immunological characteristics in COVID-19 patients remains limited. Here we collected the blood samples from 18 healthy donors (HD) and 38 COVID-19 patients to analyze changes in the adaptive immune cell populations and phenotypes. In comparison to HD, the lymphocyte percentage was slightly decreased, the percentages of CD4 and CD8 T cells in lymphocytes are similar, whereas B cell percentage increased in COVID-19 patients. T cells, especially CD8 T cells, showed an enhanced expression of late activation marker CD25 and exhaustion marker PD-1. Importantly, SARS-CoV-2 induced an increased percentage of T follicular helpher (Tfh)- and germinal center B-like (GCB-like) cells in the blood. However, the parameters in COVD-19 patients remained unchanged across various age groups. Therefore, we demonstrated that the T and B cells can be activated normally and exhibit functional features. These data provide a clue that the adaptive immunity in most people could be primed to induce a significant immune response against SARS-CoV-2 infection upon receiving standard medical care. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial COVID-19 infection was excluded from clinical trial registrition. ### Funding Statement This work was supported by grants from Natural Science Foundation of China (No. 81820108017), Natural Science Foundation of China (No. 81771673), and COVID-19 special project of Xi'an Jiaotong University Foundation (xzy032020002). We thank all the doctors, nurses, public health workers, and patients for their contribution against SARS-CoV-2 infection. ### Author Declarations All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript. Yes All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All the data are available in the manuscript.

Single-cell landscape of immunological responses in patients with COVID-19

Single-cell landscape of immunological responses in COVID-19 patients

Overly Exuberant Innate Immune Response to SARS-CoV-2 Infection

Analysis of adaptive immune cell populations and phenotypes in the patients infected by SARS CoV 2

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Large-scale single-cell analysis reveals critical immune characteristics of COVID-19 patients

Single-cell transcriptomes of peripheral blood cells indicate and elucidate severity of COVID-19

Dynamic blood single-cell immune responses in patients with COVID-19

The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing

Inflammation and Antiviral Immune Response Associated With Severe Progression of COVID-19

Single-Cell Sequencing of Peripheral Mononuclear Cells Reveals Distinct Immune Response Landscapes of COVID-19 and Influenza Patients

COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

T cell receptor repertoires in patients with COVID-19 reveal disease severity signatures

T cell receptor β repertoires in patients with COVID-19 reveal disease severity signatures

Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19

Epigenetic Landscapes of Single-Cell Chromatin Accessibility and Transcriptomic Immune Profiles of T Cells in COVID-19 Patients

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing

Unique immunological profile in patients with COVID-19